[Hot Spots].

Qilianban Gui Faxiang: The company's stock price may have the risk of falling after a large short-term increase

Gui Faxiang (002820), which has risen for 7 consecutive trading days, issued an announcement on the evening of December 2 that the stock trading was seriously abnormal, and the company's stock price rose significantly higher than the Shenzhen Stock Exchange A Index. There has been no material change in the company's fundamentals, and there is no material information that should have been disclosed but was not disclosed.

Four-board Wanshili: The company may have the risk of falling back after the stock price rises sharply

On the evening of December 2, Wanshili (301066), which has a daily limit for 4 consecutive trading days, issued an announcement on serious abnormal fluctuations in stock trading, saying that the company has not violated the fair disclosure of information after self-inspection. The company's stock price has risen significantly in the short term, and the stock turnover rate and trading volume have been significantly enlarged, and there may be a risk that the stock price will fall back after a sharp rise.

Mitutoyo Intelligence: There have been no major changes in the current operating situation and internal and external business environment

Mitutoyo Intelligent (300276), which has a daily limit for two consecutive trading days, issued an announcement on the evening of December 2 on abnormal fluctuations in stock trading, saying that the information disclosed by the company in the early stage does not need to be corrected or supplemented, and it has not been found that the recent public media has reported undisclosed material information that may or has had a greater impact on the company's stock trading price, and the current business situation and internal and external business environment have not undergone major changes. The company, its controlling shareholders and actual controllers do not have any major matters that should be disclosed by the company but have not been disclosed, or major matters that are in the planning stage. During the period of abnormal stock fluctuations, there is no trading of the company's shares by the controlling shareholder or actual controller.

Topstar: Humanoid robot-related businesses have not yet generated actual revenue

Topstar (300607) on the evening of December 2 issued an announcement on the company's stock price changes, the company is concerned that the media will list the company as a "humanoid robot concept" related stocks, as of the date of the announcement, the company's related business has not yet generated actual income, the holding subsidiary Matrix Intelligent Control Technology (Dongguan) Co., Ltd. in the early stage of establishment, will not have an impact on the company's performance, and may face unpredictable factors or force majeure such as macro economy, industry policy changes, market competition, technology iteration, etc., There is some uncertainty about the future business situation.

Huasheng Tiancheng: As of September 30, 2024, the company's supply amount to Huawei is less than 10 million yuan

Huasheng Tiancheng (600410) issued a stock trading risk warning announcement on the evening of December 2, the company has paid attention to the cooperation between the company and Huawei and the company's AI application products, and now explains the relevant matters as follows: The main cooperation model between the company and Huawei is to purchase Huawei software and hardware products based on project construction and operation needs; As of September 30, 2024, the company's supply amount to Huawei was less than 10 million yuan; The company's AI application-related products are mainly "intelligent customer service" and "intelligent data assistant", etc., and the above-mentioned business recognition revenue accounts for a small proportion of business revenue, which does not have a significant impact on the company's performance.

Wuzhou New Year: The company's lead screw product revenue accounts for a very small proportion of the company's performance, which has no impact on performance

Wuzhou New Year (603667) issued a clarification announcement on the evening of December 2, the company's lead screw products are new products developed by the company based on the technical extension of bearing products, including trapezoidal screws, ball screw pairs, and planetary roller screws. From 2024 to the present, the cumulative invoicing income of the company's lead screw products is about 6.8 million yuan including tax, accounting for 0.22% of the company's annual operating income in 2023, accounting for a very small proportion and not affecting the company's performance. At present, the company temporarily as a secondary supplier mainly to Hangzhou company to provide lead screw products, the Hangzhou company sales of lead screw products accounted for a very small proportion of the company's operating income, the company's performance has no impact. The above-mentioned lead screw product market is still in its infancy, the current orders have little impact on the company's performance, and there are many uncertainties in the downstream market demand, please pay attention to investment risks in the future.

Business treasure: There is a risk of irrational speculation in the company's stock price

On the evening of December 2, Business Treasure (002095) issued an announcement on serious abnormal fluctuations in stock trading, saying that on December 2, 2024, the company's stock turnover rate was 33.21%, given that the company's stock price has risen greatly in the short term, but the company's fundamentals have not changed significantly, and the company's stock price has the risk of irrational speculation.

Yiming Food: Mainly engaged in the research and development, production, sales and chain operation of fresh dairy products and baked goods

Yiming Food (605179) issued a stock trading risk warning announcement on the evening of December 2, the company is mainly engaged in the research and development, production, sales and chain operation of fresh dairy products and baked goods. At present, the company's production and operation are normal, and the external environment has not undergone major changes.

Jiangsu Leili: The company's robot parts and components have not yet been supplied to the market in batches

Jiangsu Leili (300660) issued an announcement on the evening of December 2 abnormal fluctuations in stock trading, the company is concerned about the recent market attention to the concept of humanoid robots, the company's robot parts products are still in the stage of research and development and sample testing, and have not yet been supplied in batches to the market. Combined with the company's recent operating conditions, internal and external business environment analysis, the company's fundamentals have not undergone major changes recently.

Dalian electric porcelain: in the first three quarters, it is planned to distribute 10 0.54 yuan

Dalian Electric Porcelain (002606) announced on the evening of December 2 that the company plans to distribute profits in the first three quarters of 2024 as follows: based on the company's total share capital as of November 29 after deducting the number of shares held in the company's repurchase account, cash dividends of 0.54 yuan (tax included) will be distributed to all shareholders for every 10 shares, with a total cash dividend of 23.4789 million yuan.

Anjing Food's profit distribution plan for the first three quarters: 10 distributions of 9.5 yuan

Anjing Foods (603345) disclosed the profit distribution plan for the first three quarters of 2024 on the evening of December 2, and plans to distribute cash dividends of 0.95 yuan (tax included) per share to all shareholders, with a total cash dividend of 278 million yuan (tax included). On the same day, the company announced that it intends to issue overseas listed shares (H shares) and be listed on the main board of the Hong Kong Stock Exchange, and the company held the 16th meeting of the fifth board of directors and the 13th meeting of the fifth board of supervisors on November 29, and deliberated and passed the "proposal on the company's issuance of H shares and listing on the Stock Exchange of Hong Kong Limited" and other proposals. The company will fully consider the interests of existing shareholders and the situation of domestic and foreign capital markets, and select an appropriate time and issuance window to complete the issuance and listing within the validity period of the resolution of the shareholders' meeting.

[M&A and reorganization].

Valin Seiko: The actual controller Huang Yehua's family is planning a major event to suspend stock trading

Valin Seiko (603356) announced on the evening of December 2 that the company's actual controller Huang Yehua's family (Huang Yehua, Ma Xiping, Huang Chao) is planning major events, which may lead to changes in the company's controlling shareholders and actual controllers. Trading in the company's shares will be suspended from the market open on the morning of Tuesday, December 3, 2024, and the suspension is expected to last no more than 2 trading days.

Bangyan Technology: Plans to acquire 100% of the shares of Xingwang Information and Communication to resume trading

Bangyan Technology (688132) announced on the evening of December 2 that the company intends to acquire 100% of the shares of Xingwang Information Communication from 16 counterparties, including Zhang Haixin, Jinzheng Shares, Xincheng Hengfu and Xinyu Investment, by issuing shares and paying cash, and raise matching funds. The company's shares will resume trading from the market open on December 3, 2024.

Suochen Technology: A wholly-owned subsidiary plans to purchase 55% of the equity of Maisijie for 88 million yuan

Suochen Technology (688507) announced on the evening of December 2 that its wholly-owned subsidiary, Digital Technology, intends to purchase 55% of the equity of Ningbo Maisijie Technology Co., Ltd. (hereinafter referred to as "Maisjie") for 88 million yuan. After the completion of this transaction, Digital Technology will hold 55% of the equity of Maxjet (corresponding to 55% of the paid-in capital contribution) and include it in the consolidated financial statements as a holding subsidiary. Maxim focuses on the field of electronic information equipment technology, and its main business directions include special electronic information modules, lightning warning and protection equipment, marine meteorological and environmental equipment, performance simulation, etc.

Huang Shanghuang: It is planned to acquire a controlling stake in Zhancui Food

Huang Shanghuang (002695) announced on the evening of December 2 that the company intends to use its own funds or self-raised funds to acquire a controlling stake in Guangdong Zhancui Food Co., Ltd. (hereinafter referred to as "Zhancui Food"). At present, the two parties have signed a confidentiality agreement, and the matter is still in the preliminary planning stage, and the transaction plan still needs to be further demonstrated, communicated and negotiated, and there are uncertainties. This outbound investment is not expected to meet the conditions for major asset restructuring, and does not constitute a material asset restructuring or related party transaction.

Kexinyuan: It plans to acquire 51% of the shares of Dongguan Zhaoke

Kexinyuan (300731) announced on the evening of December 2 that the company intends to acquire 51% of the equity of Dongguan Zhaoke Electronic Materials Technology Co., Ltd. (hereinafter referred to as "Dongguan Zhaoke") held by Thermazig Limited in cash, and the final acquisition ratio is determined by all parties through negotiation. After the completion of this transaction, the company will obtain control of Dongguan Zhaoke. The target company of this transaction is Dongguan Zhaoke, and includes its subsidiaries Kunshan Zhaoke Electronic Materials Co., Ltd., Zhaoke Technology Co., Ltd., and Vietnam Ziitek Technology Co., Ltd (Vietnam Zhaoke Technology Co., Ltd.), which are 100% directly or indirectly held after the restructuring. According to the agreement, the overall valuation of Dongguan Zhaoke will not exceed 450 million yuan, and the transaction consideration will not exceed 229.5 million yuan.

TCL Central: Participated in the restructuring of Maxeon and was reviewed and approved by the Committee on Foreign Investment in the United States

TCL Zhonghuan (002129) announced on the evening of December 2 that the company and Maxeon jointly submitted a joint voluntary declaration to the Committee on Foreign Investment in the United States ("CFIUS") for their participation in the restructuring of Maxeon. After CFIUS reviewed and signed the relevant national security agreement, CFIUS determined that there were no unresolved national security concerns related to TCL Zhonghuan's (or its subsidiaries') investment in Maxeon. Accordingly, the CFIUS review involved in this transaction has been completed. The Company and Maxeon will continue to pursue a significant strategic restructuring of their business portfolios and key geographic markets.

[Change in equity].

Weir shares: Yu Renrong Education Foundation plans to donate 600,000 shares of the company free of charge

Weir shares (603501) announced on the evening of December 2 that Yu Renrong Education Foundation plans to donate 600,000 shares of the company it holds to the Oriental Institute of Technology Foundation free of charge, accounting for about 0.05% of the company's current total share capital. After the donation, Yu Renrong Education Foundation holds 0.55% of the shares, and the Oriental Institute of Technology Foundation holds 4.16% of the shares.

Donghua Energy: It is planned to transfer 55% of the equity of Tiansheng Port

Donghua Energy (002221) announced on the evening of December 2 that the company's board of directors deliberated and approved the proposal to agree that the company and Guangxi Oceanpower Energy Co., Ltd. signed the "Agreement on the Equity Transfer of Guangxi Tiansheng Port Co., Ltd.", and transferred 55% of the equity of Tiansheng Port to Guangxi Haichuan at a transaction price of 308 million yuan. After the completion of this transaction, the company will hold 45% of the equity of Tiansheng Port, and Tiansheng Port will no longer be included in the company's consolidated financial statements. It is expected that this agreement will not have a significant impact on the company's production and operation and current year's results.

TusEnvironment: It plans to sell 49% of the equity of Zhengzhou Luyuan

TusEnvironment (000826) announced on the evening of December 2 that the company recently agreed to sell 49% of the equity of Zhengzhou Luyuan Food Waste Treatment Co., Ltd. (hereinafter referred to as "Zhengzhou Luyuan") after the approval of the company's general manager's office meeting, with a transaction consideration of 67.1842 million yuan. After the completion of this transaction, the company will no longer hold the equity of Zhengzhou Luyuan.

Nanwei Software: The controlling shareholder intends to transfer 5.85% of the company's shares by agreement

Nanwei Software (603636) announced on the evening of December 2 that Wu Zhixiong, the controlling shareholder, intends to transfer 33.952 million unrestricted tradable shares held by him to Tianjin Qizhong Shiyuan Enterprise Management Partnership (Limited Partnership), accounting for 5.8502% of the company's total share capital, at a transfer price of 10.98 yuan per share, and the share transfer price is about 373 million yuan. This change in equity will not lead to a change in the controlling shareholder and actual controller of the company.

[increase and decrease in holdings, repurchase].

Jinbei Automobile: It is planned to repurchase the company's shares for 50 million yuan - 55 million yuan

Jinbei Automobile (600609) announced on the evening of December 2 that it intends to repurchase the company's shares for 50 million yuan - 55 million yuan, all of which will be used to cancel and reduce the company's registered capital, and the price of the repurchased shares will not exceed 10.19 yuan per share.

BESTORE: Dayong Co., Ltd. has reduced its holdings of 5% of the company's shares

BESTORE (603719) announced on the evening of December 2 that from January 10 to November 29, 2024, Dayong Co., Ltd. (hereinafter referred to as "Dayong Co., Ltd.") has cumulatively reduced its holdings of 20.05 million shares of the company through centralized bidding and block trading, accounting for 5.00% of the company's total share capital, and the proportion of shares held in the company has decreased from 25.30% to 20.30%.

Longjiang Transportation: Suiyong Holdings plans to reduce its holdings of no more than 3% of the company's shares

Longjiang Transportation (601188) announced on the evening of December 2 that Suiyong Holdings, a shareholder holding 8.05% of the shares, intends to reduce its total holdings of the company's shares by centralized bidding and block trading not more than 39,476,400 shares, that is, no more than 3% of the company's total share capital. The reduction will be carried out within three months after 15 trading days from the date of disclosure of the announcement.

Pan Asia Micro Penetration: Shareholder Nanfang Precision intends to reduce its holdings of no more than 3% of the company's shares

Pan Asia Micro Penetration (688386) announced on the evening of December 2 that Nanfang Precision (002553), a 7.98% shareholder, plans to reduce the total number of shares of the company held by it through centralized bidding and block trading, which does not exceed 210,000 shares, that is, no more than 3% of the company's total share capital.

Exploration shares: shareholders are expected to reduce their holdings of no more than 1.61% of the company's shares in total

Exploration shares (603458) announced on the evening of December 2 that shareholders Guan Xiaoqing, Jia Long, Luo Laiming and Yang Shengbo hold a total of 2.6% of the company's shares, and plan to reduce their holdings of the company's shares through centralized bidding, with a total of no more than 4,934,300 shares (including the number of shares), that is, no more than 1.61% of the company's current total share capital.

Warner Pharmaceutical: Shareholders plan to reduce their holdings of no more than 1.44% of the company's shares

Huana Pharmaceutical (688799) announced on the evening of December 2 that Xu Xiaoqiang and Xu Yuehan, shareholders of the company with a total of 2.93% of the shares, plan to reduce their holdings of the company's shares by no more than 1.352 million shares, that is, no more than 1.44% of the company's total share capital. The above-mentioned shareholders are persons acting in concert.

[Business data].

SAIC: Vehicle sales in November were 478,800 units, down 7.06% year-on-year

SAIC Motor (600104) announced on the evening of December 2 that vehicle sales in November were 478,800 units, a year-on-year decrease of 7.06%; The cumulative sales volume was 3.53 million units, a year-on-year decrease of 19.48%. Among them, the sales volume of new energy vehicles in November was 174,900, a year-on-year increase of 16.06%; The cumulative sales volume was 1.08 million units, a year-on-year increase of 19.53%.

Jiangling Motors: Sales in November increased by 9.98% year-on-year

Jiangling Motors (000550) announced on the evening of December 2 that it sold 32,713 vehicles in November, a year-on-year increase of 9.98%; The cumulative sales volume this year was 305,700 units, a year-on-year increase of 10.76%.

Changyuan Power: In November, the company's power generation increased by 15.5% year-on-year

Changyuan Power (000966) announced on the evening of December 2 that the company completed power generation of 3.141 billion kWh in November, a year-on-year increase of 15.5%. From January to November 2024, the company has completed a total of 36.098 billion kWh of power generation, a year-on-year increase of 23.04%.

Far Eastern Group Co., Ltd.: In November, the subsidiary won the bid/signed a contract order of more than 10 million yuan, with a total of 1.791 billion yuan

Far Eastern Group (600869) announced on the evening of December 2 that in November 2024, the company received a total of 1.791 billion yuan of contract orders from subsidiaries that won bids/signed contracts of more than 10 million yuan.

Ningbo Port: Container throughput in November is expected to increase by 22% year-on-year

Ningbo Port (601018) announced on the evening of December 2 that the company is expected to complete a container throughput of 4.05 million TEUs in November, a year-on-year increase of 22%; It is estimated that the cargo throughput will be 91.62 million tons, a year-on-year increase of 11.9%.

[Winning the Contract].

Seiko Technology: Signed a major sales contract with Saudi GIM Company

Seiko Technology (002006) announced on the evening of December 2 that the company signed a sales contract with Graphene Fibre Limited T/a GIM GrapheneFibre (hereinafter referred to as "Saudi GIM Company"), with a total contract amount of 172 million US dollars (CIF price, the same below). According to the contract, the company will provide six production lines to Saudi GIM in phases, of which the first production line will be executed after the signing of this contract, the second production line will be executed in the third quarter of 2025, the third production line will be executed in the fourth quarter of 2025, and the remaining three will be executed in 2026. At the same time, the parties agreed that after the signing of this contract, the buyer guarantees to purchase 3 production lines from the seller every year, and the total number of production lines shall not be less than 18 (including the aforementioned 6), and the total purchase amount shall be about 500 million US dollars. The specifications and prices of the new production line will be adjusted separately.

Parsons Brinckerhoff: Pre-won the bid for a professional engineering project of 424 million yuan

Parsons Brinckerhoff (601133) announced on the evening of December 2 that the company became the first winning candidate for the professional project of the public power system project of the 11th Design and Research Institute of Information Industry Electronics Science and Technology Engineering Co., Ltd. The amount of the tender quotation is 424 million yuan.

Changlu Co., Ltd.: The subsidiary signed a general contracting contract for a construction project of 260 million yuan

Changlu Co., Ltd. (002160) announced on the evening of December 2 that its subsidiary Shanghai Langmai and Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. (hereinafter referred to as "Zhonghui Biotechnology") signed a general contracting contract for the construction project of the new influenza vaccine industrialization base, with a contract amount (including tax) of 260 million yuan. The signing and smooth implementation of this contract is conducive to improving the company's influence in the medical clean market.

Longquan shares: a wholly-owned subsidiary pre-won the bid for a procurement project of 69.5357 million yuan

Longquan Co., Ltd. (002671) announced on the evening of December 2 that Xinfeng Pipe, a wholly-owned subsidiary of the company, was identified as the winning candidate for the "CS Project LOT140Wa Non-nuclear Pipeline and Pipeline Accessories", with a bid price of 69.5357 million yuan, accounting for about 6.28% of the company's audited operating income in 2023.

Jinzhi Technology: Won the bid of 30.0739 million yuan for smart energy-related projects

Jinzhi Technology (002090) announced on the evening of December 2 that the company recently won the bid for the secondary equipment procurement project of the 220kV booster gathering station of the second phase of the 500,000 kilowatt project of the Shenzhen Energy Shule 2 million kilowatt photovoltaic and storage integration project, with a winning bid amount of 30,073,930 yuan. The counterparty of the winning project is Shenzhen Energy Shule New Energy Development Co., Ltd., a wholly-owned subsidiary of Shenzhen Energy (000027).

Yueyang Forest Paper: Chengtong Carbon Sink, a wholly-owned subsidiary, won the bid for the voluntary greenhouse gas emission reduction project in Anyuan County

Yueyang Forest Paper (600963) announced on the evening of December 2 that its wholly-owned subsidiary, Chengtong Carbon Sink, recently participated in the public bidding for the Anyuan County Greenhouse Gas Voluntary Emission Reduction Project (Forestry Carbon Sequestration Development), and received the "Transaction Notice" on December 2, 2024, becoming the winning bidder of the project, with a cooperation period of 20 years, and it is expected that at least 20 million yuan of net profit will be generated during the cooperation period.

Zhonghong Medical: The company and its subsidiaries are to be selected for participating in the centralized procurement project

Zhonghong Medical (300981) announced on the evening of December 2 that the company and its holding subsidiary Hengbao Health recently participated in the bidding for the centralized procurement and procurement project of in vitro diagnostic reagents in Aksu in 2024. The results of the proposed selection in the in vitro diagnostic reagent bargaining and centralized procurement system in Aksu show that some products of the company and Hengbao Health are planned to be selected for the above-mentioned centralized procurement projects.

[Significant investment].

Leisai Intelligence: It is planned to invest no less than 500 million yuan to build a regional headquarters in South China and a research and development intelligent manufacturing base for core components of humanoid robots

Leisai Intelligent (002979) announced on the evening of December 2 that on November 29, the company signed the "Project Investment Agreement" with the Management Committee of Dongguan Binhaiwan New Area, which stipulates that the company intends to invest no less than 500 million yuan in Dongguan Binhaiwan New Area to build Leisai Intelligent South China Regional Headquarters and Humanoid Robot Core Components R&D and Intelligent Manufacturing Base Project.

China State Construction: A subsidiary invested in a real estate development project in Nanshan District, Shenzhen

China State Construction (601668) announced on the evening of December 2 that the company's board of directors deliberated and approved the proposal of its subsidiary China Overseas Land & Investment Co., Ltd. (hereinafter referred to as "China Overseas Land") to invest in the real estate development project of Houhai Dengliang Road in Nanshan District, Shenzhen. Recently, China Overseas Enterprise Development Group Co., Ltd. (hereinafter referred to as "China Overseas Enterprise Development"), a subsidiary of China Overseas Land & Investment, has formed a consortium with Shenzhen Runtou Consulting Co., Ltd. (hereinafter referred to as "Shenzhen Runtou") and has obtained the right to use the land for the project. The project covers a total area of about 38,600 square meters, and the planned uses include commercial residences, business apartments, commercial, etc., with a land transfer price of 18.512 billion yuan. China Overseas Enterprise Development and Shenzhen Runtou will set up a project company to jointly develop the project according to the 50%:50% equity ratio.

Koyo Co., Ltd.: It plans to build a project with an annual output of 60 million sets of high-end new energy vehicles and precision parts for robots with an annual output of 1 billion yuan

Koyo Co., Ltd. (002708) announced on the evening of December 2 that the company intends to sign the "Project Investment Agreement" with the Management Committee of Huangshan High-tech Development Zone in Anhui Province to acquire the land use right of 100 acres in Huangshan High-tech Zone, Anhui Province, for the construction of a project with an annual output of 60 million sets of high-end new energy vehicles and precision parts for robots, which will be invested and constructed by Huangshan Koyo Transmission Technology Co., Ltd., a wholly-owned subsidiary of the company. The total investment of the project is expected to be 1 billion yuan (including tax, the final total investment is subject to the actual investment), and the source of funds is its own funds and self-raised funds.

Jihong Co., Ltd.: It is planned to set up an overseas joint venture company and invest in the construction of a production base and trade platform

Jihong shares (002803) announced on the evening of December 2 that the company intends to jointly invest with VENUS TRADING FZCO to set up a joint venture company AJTHolding International Limited (Chinese name: Aijiti International Holdings Co., Ltd.) in Dubai International Financial Center, United Arab Emirates, with a registered capital of 1 million dirhams (about 1.97 million yuan), and the company or its subsidiaries hold 45% of the shares, VENUS TRADING FZCO or its subsidiaries hold 55% of the shares, and with the joint venture company as the main investor, it will invest in the construction of packaging production bases and trading platforms in Ras Al Khaimah and Salala, Oman, UAE. The total investment amount of the project is expected to be 136 million US dollars (about 976 million yuan), and the total amount of foreign investment planned by the company is 61 million US dollars (about 440 million yuan).

Tianjian shares: It is planned to invest no more than 500 million yuan in the health and medical headquarters project

Tianjian Co., Ltd. (301383) announced on the evening of December 2 that the company intends to use its own funds to invest in the health and medical headquarters project in Rongjiang New District, Ganzhou, Jiangxi Province, with a total investment of no more than 500 million yuan, and signed the "Project Investment Contract" with the Management Committee of Rongjiang New District, Ganzhou.

Yunnan Energy Investment: The subsidiary plans to invest 464 million yuan in the expansion project of Laojianshan Wind Farm

Yunnan Energy Investment (002053) announced on the evening of December 2 that the company's wholly-owned subsidiary, Dayao Yunneng Investment New Energy Development Co., Ltd., plans to invest in the construction of the Laojianshan Wind Farm Expansion Project, with a total installed capacity of 75,000 kilowatts and a total investment of 464 million yuan. According to the feasibility study report of the project, the financial internal rate of return of the project capital is 8.22% based on the feed-in tariff of 0.2832 yuan/kW·h, and the economy of the project is good.

Qinchuan Machine Tool: A wholly-owned subsidiary plans to invest in the technical transformation and industrialization project of high-precision and complex tools

Qinchuan Machine Tool (000837) announced on the evening of December 2 that Hanjiang Tools Co., Ltd., a wholly-owned subsidiary of the company, plans to implement the "high-precision and complex tool technical transformation and industrialization project", with a total investment of 51.3 million yuan and a project construction period of 2 years.

Wanwei High-tech: The wholly-owned subsidiary plans to invest in the construction of a 10,000 tons/year VAE redispersible latex powder technical transformation project

Wanwei High-tech (600063) announced on the evening of December 2 that its wholly-owned subsidiary, Guangxi Wanwei, plans to invest in the construction of a 10,000 tons/year VAE redispersible latex powder technical transformation project, with a total investment of 28.7732 million yuan. The company announced on the same day that it plans to invest 26 million yuan to build an ultra-low emission technical transformation project for the cement branch.

Golden Horse Amusement: It is planned to cooperate with Zhongshan Overseas Chinese Town to operate the Zhongshan Science and Technology Park project

Golden Horse Amusement (300756) announced on the evening of December 2 that the company intends to cooperate with Zhongshan Overseas Chinese Town to operate the Zhongshan Science and Technology Park project, with a cooperation period of 10 years. Within the scope of cooperation, the company can cooperate with Zhongshan OCT to operate and manage the venues and assets in Zhongshan Science and Technology Park, as well as to carry out business management, commercial and cultural tourism operations, property and venue management and other matters through the addition of amusement equipment, landscaping, leisure facilities, etc. The company pays the cooperative operation money to Zhongshan OCT every year and the share of the cooperative operation money (if any) after meeting the agreed conditions, and promises to invest no less than 40 million yuan in the cooperation project within 10 years to increase the number of attractions or improve the quality of the scenic spot (among them, the investment amount shall be not less than 25 million yuan within 3 years from the date of signing the cooperation agreement).

[Other].

Bank of Communications: Gu Bin's qualifications to serve as the company's vice president were approved by the regulator

Bank of Communications (601328) announced on the evening of December 2 that it received the "Reply of the State Financial Supervision and Administration on the Qualifications of Gu Bin as Vice President of Bank of Communications", and Gu Bin's qualification as the vice president of the company was approved by the State Administration of Financial Supervision and Administration.

Haixiang Pharmaceutical: Huayi Taikang, a shareholding company, was approved to be listed on the New Third Board

Haixiang Pharmaceutical (002099) announced on the evening of December 2 that Huayi Taikang Pharmaceutical Co., Ltd. (hereinafter referred to as "Huayi Taikang"), a shareholding company with 1.85% of the company's shares, recently received the "Letter on Agreeing to the Public Transfer of Shares of Huayi Taikang Pharmaceutical Co., Ltd. and Listing on the National Equities Exchange and Quotations System" issued by the National Small and Medium-sized Enterprises Share Transfer System Co., Ltd., agreeing to the public transfer of Huayi Taikang shares and listing on the National Small and Medium-sized Enterprises Share Transfer System (hereinafter referred to as the "New Third Board"). The trading method is a call auction transaction.

Ling Yunguang: The shareholding company was officially listed on the New Third Board

Lingyunguang (688400) announced on the evening of December 2 that it recently learned from the shareholding company Hunan Chiopt Optoelectronics Technology Co., Ltd. (hereinafter referred to as "Chiopt") that it will be listed for public transfer in the national SME share transfer system from December 3, 2024. As of December 2, 2024, the company held a 2.23% stake in Chiopt.

Dingjide: Signed the "Catalyst Supply Framework Agreement" with Rumus Ningbo

Dingjide (603255) announced on the evening of December 2 that the company recently signed the "Catalyst Supply Framework Agreement" with Lummus (Ningbo) Engineering Technology Co., Ltd. (hereinafter referred to as "Lummus Ningbo"). Rumus Ningbo intends to purchase DJD-Z-2, DJD-Z-5 type catalysts from the Company in accordance with the terms and conditions of this Agreement, which are subsequently sold by the Buyer to licensees of the Noralen polypropylene process.

RHEINLAND: Signed a framework agreement on development cooperation with the Dead Sea Management Committee of China

Rheinland Sports (000558) announced on the evening of December 2 that the company and the Suining China Dead Sea Tourism Resort Management Committee (hereinafter referred to as the "China Dead Sea Management Committee") signed the "Suining British Film and Television City Film and Television Cultural Tourism Integration Development Cooperation Framework Agreement". The two sides will cooperate to promote the diversified development of film and television in Daying County, take film and television cultural tourism as the traction, give full play to the advantages of both sides, dig deep into market opportunities, deepen cooperation in the field of cultural industry, promote the high-quality integrated development of regional tourism, culture and film and television industries, and build a comprehensive resort area for film and television tourism.

Beijing Cree: Signed an investment intent agreement with the People's Government of Hechuan District, Chongqing

Beijing Cree (002350) announced on the evening of December 2 that recently, the company signed the "Investment Agreement" with the People's Government of Hechuan District, Chongqing, and reached the following agreement on the company's investment in the construction of an independent energy storage power station project in Hechuan District: 1. The total investment of the Huayuan independent energy storage power station project in Hechuan District, Chongqing is about 1.06 billion yuan, and it is planned to build a 400MW/800MWH energy storage power station. 2. The total investment of the distributed energy storage power station (user side) project in Hechuan District, Chongqing is about 250 million yuan, and about 200MWH of user-side energy storage facilities will be invested and built for large-scale energy-consuming enterprises in Hechuan District. 3. The total investment of Weituo independent energy storage power station project in Hechuan District, Chongqing is about 520 million yuan, and it is planned to build a 200MW/400MWH energy storage power station. 4. Combined with the industrial supporting situation of Hechuan District and the company, it is planned to invest in the construction of relevant intelligent manufacturing bases.

Aisid: It is planned to carry out foreign exchange hedging business of no more than 300 million US dollars

Aisid (002416) announced on the evening of December 2 that the company and its holding subsidiaries plan to carry out foreign exchange hedging business related to daily business needs, for the purpose of avoiding and preventing exchange rate risks, and not to carry out speculation and arbitrage transactions solely for the purpose of profit. The total amount of the above-mentioned business shall not exceed 300 million US dollars (or its equivalent in foreign currency), and the funds can be used on a rolling basis within the scope of the above-mentioned quota.

Yiduoli: A wholly-owned grandson company signed an exclusive equipment transfer contract

Yiduoli (300381) announced on the evening of December 2 that Hunan Kangjie Biotechnology Co., Ltd. (hereinafter referred to as "Hunan Kangjie"), a wholly-owned subsidiary of the company, and Huasai Biotechnology (Changde) Co., Ltd. (hereinafter referred to as "Huasai Technology") signed the "Hunan Kangjie Nucleoside Fermentation Intermediate Post-processing Workshop Exclusive Equipment Transfer Contract". Now, due to the change of the cooperation model between the two parties, the production and processing of the above-mentioned products by Huasai Technology has been changed from full entrustment to partial entrustment, so Hunan Kangjie will transfer the relevant exclusive equipment to Huasai Technology. The original book value of the exclusive equipment transferred this time was 30.2525 million yuan, and the transaction price was 35.8028 million yuan (tax included) after negotiation between the two parties.

Zhongcheng shares: Chairman Zhang Peng resigned

Zhongcheng shares (000151) announced on the evening of December 2 that Zhang Peng resigned from the company's chairman, director and special committee of the board of directors due to work transfer, and he did not hold any position in the company and the company's holding subsidiaries after his resignation.

Xinmai Medical: The total amount of taxes and late fees to be paid is about 60 million yuan to 70 million yuan

Xinmai Medical (688016) announced on the evening of December 2 that the company recently received the "Notice of Tax Matters" from the Second Tax Office of the Pudong New Area Taxation Bureau, and the company was disqualified as a high-tech enterprise because the company did not fill in the annual development report of the enterprise for two years. According to the company's preliminary calculation, the total amount of taxes and late fees to be paid is about 60 million yuan to 70 million yuan, and the impact on net profit is expected to account for more than 10% of the company's audited net profit in the latest fiscal year. The company has submitted a written objection to the announcement of the cancellation of the qualification of high-tech enterprises, and continues to communicate with relevant departments. On October 12, 2024, the Shanghai High-tech Enterprise Accreditation Office issued the "Notice on Publicizing the Second Batch of High-tech Enterprises to be Recognized in Shanghai in 2024", and the company was among them. The ICP filing process is now ongoing.

Kaipu Biotech: The company and its subsidiaries have been authorized invention patents

Kaipu Biotech (300639) announced on the evening of December 2 that the company and its subsidiaries were authorized for an invention patent in Europe in November 2024. The name of the invention patent is a method for isolating placental trophoblast cells from the exfoliated cells of the cervix of pregnant women. The invention will be applied to the field of prenatal screening and prenatal diagnosis, and has obtained invention patent certificates issued by China, the United States, Japan, Russia, Brazil, South Korea, Australia and Europe and other countries or regions, which is the first achievement of the company's cell segmentation project.

Youfu shares: The company and its subsidiaries signed a settlement agreement with Wang Moumou and others

Youfu shares (002427) announced on the evening of December 2 that recently, the company and its subsidiaries Zhejiang Youfu Technology Industry Co., Ltd., Huzhou Youfu Industrial Fiber Co., Ltd. and Wang Moumou, Yuan, Company A and Company B signed the "Settlement Agreement" to reach a settlement on the disputes involved between the parties. Mr. Wang, Mr. Yuan, Company A and Company B paid a total of 10 million yuan to the company, and the settlement money was paid in two installments. The Company has received the first tranche of the settlement of 5 million yuan, and the settlement received as a result of the above matters is expected to increase the profit for the year. As of the date of this announcement, the company has not received the above second installment, and there may be other unforeseen related factors, resulting in the risk that part of the payment cannot be recovered.

TXD: Wholly-owned subsidiary terminated major contracts

TXD (002845) announced on the evening of December 2 that Kunshan Riyue Tongxin Semiconductor Co., Ltd., a wholly-owned subsidiary of the company, signed the "Termination Agreement" with Riyue New Semiconductor (Kunshan) Co., Ltd., and terminated the "Packaging and Testing Project Cooperation Agreement" signed on January 5, 2022. The signing of the "Termination Agreement" is the result of the company's careful study and consensus with the other party, and will not have a material adverse impact on the company's financial and operating conditions, will not affect the company's long-term deployment and strategic planning of chip packaging and testing projects, and does not seriously damage the interests of the company and all shareholders.

Huadong Medicine: The supplementary application of ustekinumab injection for plaque psoriasis in children was accepted

Huadong Medicine (000963) announced on the evening of December 2 that the company's wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhongmei Huadong"), received the "Notice of Acceptance" issued by the National Medical Products Administration (NMPA), and the supplementary application for ustekinumab injection (R&D code: HDM3001/QX001S) for pediatric plaque psoriasis declared by Zhongmei Huadong was accepted.

Taienkang: The phase III clinical trial of pilocarpine hydrochloride eye drops, a wholly-owned subsidiary, completed the enrollment of all subjects

Taienkang (301263) announced on the evening of December 2 that recently, the phase III clinical trial of pilocarpine hydrochloride eye drops for the treatment of adult presbyopia organized by Shandong Huabo Kaisheng Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, completed the enrollment of all subjects.

Weixinkang: Calcium gluconate injection, a wholly-owned subsidiary, passed the consistency evaluation

Weixinkang (603676) announced on the evening of December 2 that its wholly-owned subsidiary, Yangpu Jingtai, received the "Notice of Approval of Drug Supplementary Application" for calcium gluconate injection approved and issued by the State Food and Drug Administration, and the drug passed the consistency evaluation of generic drug quality and efficacy. Calcium gluconate injection is suitable for acute hypocalcemia, magnesium poisoning, and fluorosis.

Walvax Biotech: Received the "Notice of Approval of Drug Clinical Trial" for adsorbed tetanus vaccine

Walvax Biotech (300142) announced on the evening of December 2 that the adsorbed tetanus vaccine jointly applied for clinical trials by the company and its holding subsidiary Yuxi Watson Biotechnology Co., Ltd. recently obtained the "Drug Clinical Trial Approval Notice" issued by the State Drug Administration, agreeing to carry out clinical trials for the prevention of tetanus.

Puluo Pharmaceutical: Obtained the approval notice of the marketing application of venlafaxine hydrochloride chemical API

Puluo Pharmaceutical (000739) announced on the evening of December 2 that recently, Zhejiang Puluo Jiayuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Jiayuan Pharmaceutical"), a wholly-owned subsidiary of the company, received the "Notice of Approval of the Marketing Application for Chemical APIs" issued by the State Food and Drug Administration. Venlafaxine is a norepinephrine and serotonin reuptake inhibitor, which is mainly used in clinical practice for the treatment of various depressions and generalized anxiety disorders, especially for depression with anxiety.

Sialon Pharmaceutical: The subsidiary obtained the registration certificate of esmolol hydrochloride injection and other drugs

Sialon Pharmaceutical (002898) announced on the evening of December 2 that Hunan Sialon Pharmaceutical (Changsha) Co., Ltd., a wholly-owned subsidiary of the company, recently obtained the "Drug Registration Certificate" of esmolol hydrochloride injection (specification: 10ml: 0.1g) and fluorouracil injection (specification: 10ml: 500mg) approved and issued by the State Food and Drug Administration. The main indications of esmolol hydrochloride injection are: for supraventricular tachycardia or uncompensated sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension. Fluorouracil injection is a Class A drug in the National Drug Catalogue of Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2024), which is mainly used for the treatment of digestive tract tumors.

Hengrui Pharmaceutical: Fluzoparib capsules and apatinib mesylate tablets obtained drug registration certificates

Hengrui Pharmaceutical (600276) announced on the evening of December 2 that it received the "Drug Registration Certificate" approved by the State Food and Drug Administration for the issuance of fluzoparib capsules and apatinib mesylate tablets, and the approved new indications are: fluzoparib monotherapy or combined with apatinib mesylate for adult patients with human epidermal growth factor receptor (HER2) negative metastatic breast cancer with germline BRCA mutation (gBRCAm) who have received chemotherapy treatment in the neoadjuvant, adjuvant or metastatic stages. Patients with hormone receptor (HR)-positive breast cancer who have previously received endocrine therapy or are considered unsuitable for endocrine therapy.

Xinhua Pharmaceutical: Obtained the "Notice of Approval of Drug Supplementary Application".

Xinhua Pharmaceutical (000756) announced on the evening of December 2 that recently, the company received the "Notice of Approval of Drug Supplementary Application" for esmolol hydrochloride injection (10ml: 0.1g) and lactulose oral solution (100ml: 66.7g) approved by the State Food and Drug Administration, and the transfer application of the marketing authorization holder of the above products was approved.

Lianhuan Pharmaceutical: Digoxin injection obtained the "Drug Registration Certificate".

Lianhuan Pharmaceutical (600513) announced on the evening of December 2 that it recently received the "Drug Registration Certificate" of digoxin injection approved and issued by the State Drug Administration, which can be used for the treatment of mild to moderate heart failure in adults, increase myocardial contractility in children with heart failure, and can be used to control atrial fibrillation with rapid ventricular rate, ventricular rate and supraventricular tachycardia in patients with atrial flutter. Recently, digoxin injection has been included in the tenth batch of national centralized drug procurement catalog, and up to now, the company has completed the registration and declaration work.

China Pharmaceutical: Atomoxetine hydrochloride capsules, a subsidiary, passed the consistency evaluation

China Pharmaceutical (600056) announced on the evening of December 2 that its wholly-owned subsidiary, Tianfang Pharmaceutical, received two copies of the "Notice of Approval of Drug Supplementary Application" for atomoxetine hydrochloride capsules approved and issued by the State Food and Drug Administration, and the drug passed the consistency evaluation of generic drug quality and efficacy. Atomoxetine hydrochloride capsules are used for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.

Sinopharm Modern: The holding subsidiary obtained two drug registration certificates

Sinopharm Modern (600420) announced on the evening of December 2 that its holding subsidiaries Sinopharm Sanyi, Sinopharm Zhijunpingshan's diquafosol sodium eye drops and sevelam carbonate tablets respectively received the "Drug Registration Certificate" approved and issued by the State Drug Administration.

ZBD: Moxifloxacin Hydrochloride Sodium Chloride Injection, a wholly-owned subsidiary, obtained the drug registration certificate

Zhenbaodao (603567) announced on the evening of December 2 that its wholly-owned subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., received the "Drug Registration Certificate" for Moxifloxacin Hydrochloride Sodium Chloride Injection issued by the State Drug Administration, and Moxifloxacin Hydrochloride Sodium Chloride Injection is used for the treatment of acute bacterial sinusitis, acute attack of chronic bronchitis, and community-acquired pneumonia caused by sensitive bacteria in adults (≥ 18 years old).

Weili Medical: A wholly-owned subsidiary, a single-use hydrophilic coating visible nasogastric tube, entered the special review procedure for innovative medical devices

Weili Medical (603309) announced on the evening of December 2 that its wholly-owned subsidiary, Hainan Weili, recently received the "Hainan Province Class II Innovative Medical Device Approval Procedure Application Notice" issued by the Hainan Provincial Drug and Medical Device Evaluation Service Center, and agreed that Hainan Weili's innovative product disposable hydrophilic coating visual nasogastrointestinal tube will enter the special review procedure for innovative medical devices. It can effectively shorten the product registration cycle and speed up the time to market.

Dongya Pharmaceutical: A wholly-owned subsidiary, cefaclor API (enzymatic method), obtained the European CEP certificate

East Asia Pharmaceutical (605177) announced on the evening of December 2 that its wholly-owned subsidiary, Zhejiang Dongbang Pharmaceutical Co., Ltd., received the CEP certificate (European Pharmacopoeia Applicability Certificate) for cefaclor API (enzymatic method) issued by the European Agency for the Quality of Medicines (EDQM), cefaclor is a second-generation cephalosporin antibacterial drug, which can be used to treat a variety of respiratory tract infections, urinary tract infections, otolaryngal infections and skin and soft tissue infections caused by sensitive bacteria.